Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1007757

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Levetiracetam
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.
	tabling member constituency	Crewe and Nantwich
	tabling member printed	Laura Smith
	uin	191984
	answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The United Kingdom’s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.</p><p> </p><p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 11:54:10 answering member 4067 label Biography information for Steve Brine
	tabling member	4648 label Biography information for Laura Smith

1007762

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has targets for improvements to care and services for people with dementia over the period of this Parliament.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	191881
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>Dementia remains a key priority for the Government. We will implement the Prime Minister’s Challenge on Dementia 2020 (published in February 2015) in full to make sure the lives of those with dementia are transformed by 2020.</p><p> </p><p>Working with our partners, we continue to make progress against the ambitions set in the March 2016 Implementation Plan which details how the commitments in the Challenge, across the four core themes of risk reduction, health and care, awareness and social action, and research will be met. This is reflected in the specific expectation set in the mandate to NHS England 2018/19 that two thirds of people living with dementia should receive a formal diagnosis. As of October 2018, the dementia diagnosis rate was 67.9%.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 20/11/2018 15:37:58 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1409 label Biography information for Mr Gregory Campbell

1007767

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nusinersen
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	191928
	answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).</p><p> </p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.</p><p> </p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE’s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:13:09 answering member 4067 label Biography information for Steve Brine
	tabling member	4249 label Biography information for Anne Marie Morris

1007772

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	191929
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191930 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

1007773

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	191930
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

1007774

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to publish the long-term plan for the NHS.
	tabling member constituency	Washington and Sunderland West
	tabling member printed	Mrs Sharon Hodgson
	uin	191894
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>The Government expects National Health Service leaders, clinicians and experts to develop the long-term plan to ensure that the NHS can cope with the serious demand and cost pressures it faces in the future. It will be published later this year.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 20/11/2018 11:14:52 answering member 1585 label Biography information for Stephen Hammond
	tabling member	1521 label Biography information for Mrs Sharon Hodgson

1007775

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	191931
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

1007776

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	HIV Infection: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	191932
	answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191931 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4267 label Biography information for Sarah Champion

1007777

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will introduce a secondary support package covering breast cancer care to include (a) access to a dedicated clinical nurse specialist, (b) an assessment of physical and emotional needs at (i) diagnosis and (ii) through treatment and referral and (c) signposting to tailored, specialist support services.
	tabling member constituency	Birkenhead
	tabling member printed	Frank Field
	uin	191871
	answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The NHS Cancer Programme is working to improve access to cancer nurse specialists (CNSs) for all cancer patients when they need it, including those with secondary breast cancer.</p><p> </p><p>We are committed to rolling out the recovery package to every cancer patient by 2020. The recovery package is a set of four interventions designed to help patients and clinicians assess a patient’s holistic needs, including physical and emotional needs, at appropriate time points through their cancer journey, as needs do change especially when a person is diagnosed with secondary cancer. A personalised care and support plan to meets these needs should be agreed, ensuring signposting and referral to the right support and care services is made, and also helping to empower patients to independently manage their own health, with advice and support.</p><p> </p><p>NHS England is committed to giving more patients access to a CNS or other specialist from diagnosis onwards to guide them through treatment options and ensure they receive appropriate information and support. In their first Cancer Workforce Plan, which was published in December 2017, Health Education England committed to supporting the expansion of CNSs by developing national competencies and a clear route into training. This will ensure that every patient has access to a CNS or other support worker by 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:20:10 answering member 4067 label Biography information for Steve Brine
	tabling member	478 label Biography information for Lord Field of Birkenhead

1007778

	registered interest
	date	15/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Suicide: LGBT+ People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the suicide prevention strategy addresses the needs of LGBT people.
	tabling member constituency	Rotherham
	tabling member printed	Sarah Champion
	uin	191933
	answer	answer is ministerial correction date of answer 23/11/2018 answer text <p>In July 2018, the Government Equalities Office published a report titled ‘Improving LGBT lives: Government action since 2010’ which is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/improving-lgbt-lives-government-action-since-2010" target="_blank">https://www.gov.uk/government/publications/improving-lgbt-lives-government-action-since-2010</a></p><p> </p><p>That report made a commitment that the Government will take action to improve mental healthcare for LGBT people and, as part of this, the Department will work with the Government Equalities Office to implement elements of its LGBT Action Plan through the National Suicide Prevention Strategy. We will set this work out in a Cross-Government Suicide Prevention Workplan which will be published shortly.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 23/11/2018 11:25:25 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	4267 label Biography information for Sarah Champion